| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| LILRA4 | Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | |||
| LILRA4 | Human LILRA4 / CD85g / ILT7 Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $360.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Daxdilimab | MEDI-7734; VIB-7734; HZN-7734 | Phase 2 Clinical | Horizon Therapeutics PLC, Sbi Biotech Co Ltd | Acute Lung Injury; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Myositis; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome | Details |